This cellular reprogramming of glucose metabolism to fuel tumor cell growth is largely thought to be driven by the AKTphosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway, which is commonly activated in endometrial carcinomas. Here, MTOR is linked to endometrial carcinoma.